Evidence, read properly

Bilberry And The Night-Vision Story That Did Not Survive Testing

Bilberry is on almost every eye supplement sold, and the reason most people can give for it is a story about wartime pilots eating jam. When somebody finally went looking for that effect in placebo-controlled trials, it was not there. What was there is smaller, more recent and considerably more useful, and almost nobody quotes it.

Evidence, read properly · Visivra Team at Govisivra · physician review: Dr. Preston Sullivan, MD · last revised September 30, 2026

The story everyone repeats

The version you will find repeated across the category goes roughly like this. During the Second World War, British night-fighter crews ate bilberry jam before sorties and found their night vision improved. Somebody later isolated the anthocyanins, and a supplement category was born.

It is a good story. It has aircrew in it, it has a homely food, and it has the shape of a discovery. What it does not have is a trial, a squadron, a name or a date that anyone has been able to produce. It circulates because it is repeated, and it is repeated because it is easy to repeat.

None of which would matter if the underlying claim were true. Plenty of real findings have an apocryphal origin story attached. The problem with this one is that when the claim was finally examined properly, it did not hold.

What happened when somebody tested it

In 2004, Canter and Ernst published a systematic review of placebo-controlled trials of bilberry anthocyanosides for night vision. Systematic review means they set the inclusion criteria first and then went looking, rather than collecting the studies that supported a conclusion they already held.

They found twelve trials. Seven of them were placebo-controlled and five were not. Of the five uncontrolled trials, all five reported a positive effect. Of the seven controlled trials, four found nothing and one found an effect in a small number of subjects that the authors themselves were cautious about.

That pattern is one of the most familiar in the whole of clinical research, and it is worth naming plainly. When a treatment works only in the studies that did not control for expectation, the most economical explanation is that what was being measured was expectation.

Why night vision is especially easy to get wrong

Dark adaptation is a slow physiological process and it is also an intensely subjective experience. A person who has just taken something they believe helps them see in the dark will sit in a dark room paying close attention to how well they are seeing, which is itself enough to change what they report.

Controlled testing exists precisely for outcomes like this one. It is also why the two bilberry findings that did survive are worth more than their modest size suggests: one of them measured a muscle rather than an impression.

Four claims, one source each, two different outcomes. The failure and the successes come from the same plant and the same class of compound.

What did survive: two trials worth reading

The modern bilberry evidence is about focusing and fatigue, and it is about eight to twelve weeks rather than about a single dose before a night drive.

The first is a twelve-week randomised, double-blind, placebo-controlled trial that gave 240 mg of standardised extract a day and measured objective findings of ciliary-muscle contraction. The ciliary muscle is the one that changes the shape of the lens to move focus between near and far. It is a muscle, it is measurable, and it is not susceptible to the reporting problem above.

The second is an eight-week trial in display-terminal workers at 480 mg a day, which measured subjective eye fatigue and found it lower. That one is a self-report measure, but it was placebo-controlled, and it is the outcome most screen-heavy buyers actually care about.

A third, a 2011 combination trial, gave bilberry alongside fish oil and lutein and reported improvement in asthenopia symptoms. It is honest evidence about a combination and it cannot tell you which ingredient did the work, which is a limitation rather than a flaw.

A twofold difference between the two single-ingredient amounts, and both are extract weights rather than anthocyanin weights.

Why the extract weight is not the active weight

Here is the part that makes comparing two bilberry labels genuinely hard, and it applies even when both of them print a number.

The figures above, 240 mg and 480 mg, are weights of extract. An extract is plant material processed and concentrated, and the concentration is set by the manufacturer. Trial-grade bilberry extract is usually standardised to around 36 per cent anthocyanosides, which is where those two amounts get their meaning. An extract standardised to 5 per cent, given at the same 240 mg, delivers roughly a seventh of the active compound.

So a label that prints 240 mg of bilberry extract and nothing else has told you one of the two numbers you need. The second one is the standardisation, and it is the one that decides whether the first one means anything.

• Extract weight is how much powder went into the capsule.
• Standardisation is what fraction of that powder is the active compound, usually written as a percentage of anthocyanosides.
• Ratio extracts such as 100:1 describe how much raw fruit was reduced to make the powder, which is a different statement again and is not interchangeable with a standardisation.
• Whole fruit powder is not an extract at all and carries a small fraction of the anthocyanins by weight.

None of this is a reason to distrust bilberry. It is a reason to read a bilberry row carefully, and to notice that a great many labels give you neither number. A review of nutrition and digital eye strain makes a related point about the field as a whole: the ingredients are plausible, the trials are small, and the reporting is inconsistent enough that comparing across them is harder than it looks.

Four questions to ask of any bilberry label

1. Does it give an amount at all? If not, everything below is moot.
2. Is that amount extract weight, and is the standardisation printed beside it?
3. Does the marketing lead on night vision? If it does, the label is quoting the story rather than the trials.
4. Does anything on the packaging suggest a single dose before driving? Both surviving trials ran for at least eight weeks.

What Visivra says about its own bilberry

Bilberry extract is third on the Visivra artwork, and the artwork gives no amount for it, as it gives none for the other five actives. That is set out in full on the ingredients page, and this desk does not estimate a figure anywhere.

What this desk does do is choose which evidence to cite. Every page on this website that mentions bilberry cites the ciliary-muscle trial and the screen-worker trial, and every one of them also cites the systematic review that found the night-vision claim unsupported. The easiest paragraph in this category to write is the wartime one, and it does not appear anywhere on this site.

That is a small decision and it is the kind that accumulates. A reader who catches a website repeating a claim they know to be false has no way of telling which of the other claims to trust.

The bottom line

Bilberry belongs in an eye formula, and it belongs there for reasons almost nobody cites. Two placebo-controlled trials, one measuring a muscle and one measuring fatigue, over eight and twelve weeks, at 240 and 480 mg of standardised extract a day. That is a modest, real, recent evidence base.

The night-vision claim is not part of it and has not been for twenty years. A label leading on it in 2026 has either not read the review or has decided the story sells better, and either answer is useful to a buyer.

If you are comparing bottles, ask for the extract weight and the standardisation. If a label gives neither, you are buying the ingredient rather than a dose, and that is a legitimate thing to buy as long as you know that is what it is. The nine-question checklist sets out how much weight to put on it.

References